Cargando…
Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer
Antibody targeting of tumor-associated vasculature is a promising therapeutic approach in human cancer; however, a specific cell membrane marker for endothelial cells of tumor vasculature has not been discovered yet. Endoglin (CD105) is a cell-surface glycoprotein most recently identified as an opti...
Autores principales: | , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC441416/ https://www.ncbi.nlm.nih.gov/pubmed/15193152 http://dx.doi.org/10.1186/1479-5876-2-18 |
_version_ | 1782121544041889792 |
---|---|
author | Fonsatti, Ester Maio, Michele |
author_facet | Fonsatti, Ester Maio, Michele |
author_sort | Fonsatti, Ester |
collection | PubMed |
description | Antibody targeting of tumor-associated vasculature is a promising therapeutic approach in human cancer; however, a specific cell membrane marker for endothelial cells of tumor vasculature has not been discovered yet. Endoglin (CD105) is a cell-surface glycoprotein most recently identified as an optimal indicator of proliferation of human endothelial cells. The finding that CD105 is over-expressed on vascular endothelium in angiogenetic tissues has prompted several pre-clinical studies designed to get a deeper understanding on the role of CD105 in angiogenesis, and to evaluate the most appropriate clinical setting(s) to utilize CD105 as a therapeutic target. In this review, the foreseeable clinical applications of CD105 in human cancer are discussed. |
format | Text |
id | pubmed-441416 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2004 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-4414162004-07-02 Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer Fonsatti, Ester Maio, Michele J Transl Med Review Antibody targeting of tumor-associated vasculature is a promising therapeutic approach in human cancer; however, a specific cell membrane marker for endothelial cells of tumor vasculature has not been discovered yet. Endoglin (CD105) is a cell-surface glycoprotein most recently identified as an optimal indicator of proliferation of human endothelial cells. The finding that CD105 is over-expressed on vascular endothelium in angiogenetic tissues has prompted several pre-clinical studies designed to get a deeper understanding on the role of CD105 in angiogenesis, and to evaluate the most appropriate clinical setting(s) to utilize CD105 as a therapeutic target. In this review, the foreseeable clinical applications of CD105 in human cancer are discussed. BioMed Central 2004-06-11 /pmc/articles/PMC441416/ /pubmed/15193152 http://dx.doi.org/10.1186/1479-5876-2-18 Text en Copyright © 2004 Fonsatti and Maio; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL. |
spellingShingle | Review Fonsatti, Ester Maio, Michele Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer |
title | Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer |
title_full | Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer |
title_fullStr | Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer |
title_full_unstemmed | Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer |
title_short | Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer |
title_sort | highlights on endoglin (cd105): from basic findings towards clinical applications in human cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC441416/ https://www.ncbi.nlm.nih.gov/pubmed/15193152 http://dx.doi.org/10.1186/1479-5876-2-18 |
work_keys_str_mv | AT fonsattiester highlightsonendoglincd105frombasicfindingstowardsclinicalapplicationsinhumancancer AT maiomichele highlightsonendoglincd105frombasicfindingstowardsclinicalapplicationsinhumancancer |